A PHASE 1, OPEN LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY/TOLERABILITY OF CC-90001 IN JAPANESE HEALTHY SUBJECTS
Latest Information Update: 13 Aug 2021
At a glance
- Drugs BMS 986360 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
Most Recent Events
- 26 Jun 2021 Results presented at The International Liver Congress 2021
- 06 May 2020 Status changed from recruiting to completed.
- 23 May 2019 New trial record